Trial Profile
A Phase 3, Multicenter, Open Label, Study to Evaluate the EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With Steroid Resistant Acute Graft Versus Host Disease (SR-aGvHD)
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs Inolimomab (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms EiFFEL
- Sponsors ElsaLys Biotech
- 15 Dec 2020 Planned initiation date changed from 1 Oct 2020 to 1 Oct 2021.
- 27 Feb 2020 Status changed from planning to not yet recruiting.
- 11 Apr 2018 New trial record